Literature DB >> 18434341

A case-control study of community-associated Clostridium difficile infection.

M H Wilcox1, L Mooney, R Bendall, C D Settle, W N Fawley.   

Abstract

OBJECTIVES: The aim of this study was to determine the incidence of and risk factors for community-associated Clostridium difficile infection (CDI).
METHODS: Prospective surveillance of community-derived faecal samples for C. difficile cytotoxin, followed by a questionnaire-based case-control study in two distinct patient cohorts (one semi-rural and the other urban).
RESULTS: The proportion of randomly selected faecal samples positive for C. difficile cytotoxin was 2.1% in both patient cohorts (median ages 73 and 45 years for the urban and semi-rural cohorts, respectively). Exposure to antibiotics in the previous 4 weeks, particularly multiple agents (P < 0.001), aminopenicillins (P < 0.05) and oral cephalosporins (P < 0.05), was significantly more frequent among cases than controls. Hospitalization in the preceding 6 months was significantly associated with CDI (45% versus 23%; P = 0.022). However, almost half the cases had not received antibiotic therapy in the month before C. difficile detection, and approximately one-third neither had exposure to antibiotics nor recent hospitalization. Contact with infants aged < or =2 years was significantly associated with CDI (14% versus 2%; P = 0.02). Prior exposure to gastrointestinal-acting drugs (proton pump inhibitor, H2 antagonist or non-steroidal anti-inflammatory) was not significantly more common in CDI cases. C. difficile PCR ribotype 001 caused 60% and 13% of urban and semi-rural community-associated CDI cases, respectively.
CONCLUSIONS: Reliance on antibiotic history and age (> or =65 years) will contribute to missed diagnoses of community-associated CDI. Potential risk factors for community-associated CDI should be explored further to explain the large proportion of cases not linked to recent antibiotic therapy or hospitalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434341     DOI: 10.1093/jac/dkn163

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  123 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors:  Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

3.  Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.

Authors:  Marco Falcone; Alessandro Russo; Federica Iraci; Paolo Carfagna; Paola Goldoni; Vincenzo Vullo; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 4.  Recurrent Clostridium difficile infection and the microbiome.

Authors:  Rowena Almeida; Teklu Gerbaba; Elaine O Petrof
Journal:  J Gastroenterol       Date:  2015-07-08       Impact factor: 7.527

Review 5.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

6.  Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance.

Authors:  Jessica A Ferreyra; Katherine J Wu; Andrew J Hryckowian; Donna M Bouley; Bart C Weimer; Justin L Sonnenburg
Journal:  Cell Host Microbe       Date:  2014-12-10       Impact factor: 21.023

7.  Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis.

Authors:  Jane W Marsh; Mary M O'Leary; Kathleen A Shutt; Susan P Sambol; Stuart Johnson; Dale N Gerding; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2009-12-02       Impact factor: 5.948

Review 8.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

Review 9.  Clostridioides difficile Infection.

Authors:  Alice Y Guh; Preeta K Kutty
Journal:  Ann Intern Med       Date:  2018-10-02       Impact factor: 25.391

10.  Clostridium difficile infection is associated with increased risk of death and prolonged hospitalization in children.

Authors:  Julia Shaklee Sammons; Russell Localio; Rui Xiao; Susan E Coffin; Theoklis Zaoutis
Journal:  Clin Infect Dis       Date:  2013-03-26       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.